These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23154263)

  • 1. Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors.
    Pansy J; Fritsch P; Sovinz P; Lackner H; Schwinger W; Urban C; Benesch M
    Anticancer Drugs; 2013 Feb; 24(2):198-203. PubMed ID: 23154263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
    Reismüller B; Azizi AA; Peyrl A; Heinrich M; Gruber-Olipitz M; Luckner D; Rothschild KV; Slavc I
    Pediatr Blood Cancer; 2010 May; 54(5):681-6. PubMed ID: 20066713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab safety in patients with central nervous system metastases.
    Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
    Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
    Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and central nervous system (CNS) hemorrhage.
    Letarte N; Bressler LR; Villano JL
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1561-5. PubMed ID: 23564377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
    Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
    Ramasubramanian A; Shields CL
    Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in pediatric patients: how safe is it?
    de Pasquale MD; Castellano A; de Sio L; de Laurentis C; Mastronuzzi A; Serra A; Cozza R; Jenkner A; de Ioris MA
    Anticancer Res; 2011 Nov; 31(11):3953-7. PubMed ID: 22110225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
    Sanders KE; Ha CS; Cortes-Franco JE; Koller CA; Kantarjian HM; Cox JD
    Cancer; 2004 May; 100(10):2176-80. PubMed ID: 15139061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.
    Fangusaro J; Gururangan S; Jakacki RI; Kaste SC; Goldman S; Pollack IF; Boyett JM; Kun LE
    J Clin Oncol; 2013 Jan; 31(2):e24-7. PubMed ID: 23169504
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
    Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
    J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer.
    Koskas M; Chereau E; Ballester M; Selle F; Rouzier R; Daraï E
    Anticancer Res; 2010 Nov; 30(11):4743-7. PubMed ID: 21115934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.